Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from American Society of Hematology (ASH) 63rd Annual Meeting



SOMERSET, New Jersey – (COMMERCIAL THREAD) – Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biotechnology company that develops and manufactures novel therapies, today announced it will host a hybrid event featuring leaders in Key Opinion (KOL) in Multiple Myeloma on Monday, Dec. 13 at 8 p.m. ET.

The meeting will detail new and updated data from the CARTITUDE clinical development program for ciltacabtagene autoleucel (cilta-cel). Cilta-cel is an investigational T-cell therapy (CAR-T) directed by a chimeric B-cell maturation antigen (BCMA) that is being investigated for the treatment of patients with relapsed and / or refractory multiple myeloma. The meeting will follow oral and poster presentations of the studies at 63e ASH Annual Meeting and Exhibition.

Participants at the event will include Ying Huang, PhD, CEO and CFO of Legend Biotech, and the following professionals in hematology and oncology:

  • Sundar Jagannath, MD, professor of medicine, hematology and medical oncology, Mount Sinai School of Medicine; Director, Multiple Myeloma Program at Mount Sinai Hospital

  • Saad Usmani, MD, professor of medicine, Weill Cornell Medical College; Head of the Myeloma Department, Memorial Sloan Kettering Cancer Center, New York

This meeting will be accessible to investors and other interested parties by accessing the Legend Biotech website at Events and presentations.

About multiple myeloma

Multiple myeloma is an incurable cancer of the blood that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells.1 Although treatment can lead to remission, unfortunately, patients are very likely to relapse.2 Relapsed myeloma occurs when the disease has come back after a period of initial, partial, or complete remission and does not meet the definition of being refractory.3 Refractory multiple myeloma occurs when a patient’s disease either does not respond or progresses within 60 days of their last treatment.4.5 While some patients with multiple myeloma have no symptoms, most patients are diagnosed due to symptoms that may include bone problems, low blood count, elevated calcium, kidney problems, or infections.6 Patients who relapse after treatment with standard therapies, including protease inhibitors and immunomodulatory agents, have an unfavorable prognosis and few treatment options available.7

About Cilta-cel

Cilta-cel is an investigational therapy of chimeric antigen receptor (CAR-T) T cells, formerly identified as JNJ-4528 in the United States and Europe, and LCAR-B38M CAR-T cells in China, which is being studied as part of a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and in the first lines of treatment. The design consists of a structurally differentiated CAR-T with two single domain antibodies targeting BCMA. In December 2017, Legend Biotech, Inc. entered into an exclusive worldwide licensing and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel. In addition to a Revolutionary Therapy Designation (BTD) granted in the United States in December 2019, cilta-cel received a Priority Drug Designation (PRiME) from the European Commission in April 2019, and a BTD designation in China in August. 2020. Additionally, Orphan Drug designation was granted for cilta-cel by the US FDA in February 2019 and by the European Commission in February 2020. European Medicines Agency.

About Legend Biotech

Legend Biotech is a global clinical-stage biotechnology company dedicated to the treatment and cure of life-threatening diseases. Based in Somerset, New Jersey, we develop advanced cell therapies across a wide range of technology platforms, including autologous and allogeneic chimeric antigen receptor T cells, T cell receptors (TCR-T) and natural killer cells (NK). immunotherapy based. From our three R&D sites around the world, we apply these innovative technologies to continue to find safe, effective and cutting-edge treatments for patients around the world.

We are currently engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an experimental BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. Cilta-cel’s approval applications for the treatment of patients with RRMM are currently under regulatory review by several health authorities around the world, including the United States Food and Drug Administration and the European Medicines Agency. .

Learn more about www.legendbiotech.com and follow us on Twitter and LinkedIn.

Caution regarding forward-looking statements

The statements contained in this press release regarding future expectations, plans and prospects, as well as any other statements regarding matters which are not historical facts, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, the expected timing and ability to progress clinical trials, clinical data relating to the CARTITUDE studies of Legend Biotech, and the potential benefits. of our product candidates. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “have the intention of”, “can”, “for,, by” “,” of the “of the” of the “of the” of the “of” of. “should”, “target”, “will”, “should” and similar expressions are intended to identify forward-looking statements, although that all forward-looking statements do not contain these identifying words. Actual results may differ materially from those indicated by these forward-looking statements due to various important factors. Legend Biotech’s expectations could be affected, among other things, by uncertainties associated with the development of new pharmaceutical products; unexpected results of clinical trials or preclinical studies, including as a result of further analysis of existing data or unexpected new data; unexpected regulatory actions or delays, including requests for additional safety and / or efficacy data or data analysis, or government regulations in general; unforeseen delays resulting from actions taken, or failure to act, by our third party partners; uncertainties arising from Legend Biotech’s patent challenges or other proprietary intellectual property protections, including uncertainties involved in the litigation process in the United States; competition in general; government, industry and general public prices and other political pressures; the duration and severity of the COVID-19 pandemic and the government and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s annual report on Form 20-F filed with the Securities and Exchange Commission on April 2, 2021. If one or more of these risks or uncertainties materialize , or if the underlying assumptions turn out to be inaccurate, actual results may differ materially from those described in this press release as anticipated, believed, estimated or expected. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

The references

1 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/introduction. Accessed November 2020.

2 Abdi J, Chen G, Chang H et al. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013; 4: 2186-2207.

3 National Cancer Institute. NCI Dictionary of Cancer Terms: Relapse. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45866. Accessed November 2020.

4 National Cancer Institute. NCI Dictionary of Cancer Terms: Refractory. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=350245. Accessed November 2020.

5 Richardson P, Mitsiades C, Schlossman R, et al. Treatment of relapsed refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007: 317-23.

6 American Cancer Society. Multiple myeloma: early detection, diagnosis and staging. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8740.00.pdf. Accessed November 2020.

7 Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in relapsed multiple myeloma after treatment with IMiDs and bortezomib: study by an international multicenter myeloma working group. Leukemia. 2012; 26: 149-57.



Comments are closed.